Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Lung Cancer Metastatic: early-phase trial registry

5 of 9 indexed Lung Cancer Metastatic trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 5 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Lung Cancer Metastatic: 9 US clinical trials tracked, 5 recruiting.

Lung Cancer Metastatic is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 2 of these trials.

Enrollment posture brief

Registry condition lung-cancer-metastatic

OPEN 5 | RECR 56% | LATE 0 | EARLY 7 | RANK #1916 | SPON 2

Nearest open-share peer: Advanced Colorectal Cancer (56% recruiting · 9 trials)

Lung Cancer Metastatic (this)56%Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Lung Cancer Metastatic

Lung Cancer Metastatic lists 5 open slots (56% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Lung Cancer Metastatic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Lung Cancer Metastatic is recruiting above its size-band peers.

    5 of 9 indexed trials (55.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Lung Cancer Metastatic research.

    Memorial Sloan Kettering Cancer Center accounts for 2 of 9 trials (22.2%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Most Lung Cancer Metastatic trials plan to enrol fewer than 100 people.

    Median target enrolment is 38 among the 9 trials that report a genuine target (sentinel values excluded). 6 of those (66.7%) plan for fewer than 100 participants.

  4. Lung Cancer Metastatic research is mostly interventional.

    8 interventional and 1 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 22

Open and recent trials

9 total, page 1 of 1

RECRUITING 2,200 participants

I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

NCT05537922

RECRUITING Phase 1 250 participants

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

Krystal Biotech

NCT06228326

RECRUITING Phase 2 62 participants

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

Memorial Sloan Kettering Cancer Center

NCT05419076

RECRUITING Phase 1 38 participants

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Collin Blakely

NCT04085315

RECRUITING Phase 1 20 participants

Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer

University of California, Davis

NCT05452005

ACTIVE NOT RECRUITING NA 299 participants

NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer

Tufts University

NCT04986670

ACTIVE NOT RECRUITING Phase 2 38 participants

A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC

Scott Antonia

NCT05144529

ACTIVE NOT RECRUITING Phase 1 16 participants

Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer

University of Vermont

NCT04311762

COMPLETED Phase 1 24 participants

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Memorial Sloan Kettering Cancer Center

NCT03076164

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 2

Named interventions

Most-linked intervention names on Lung Cancer Metastatic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Nutrition Toolkit Behavioral
1 trials
Nutrition Assessment Other
1 trials
Nutrition Prescription Behavioral
1 trials
Medically Tailored Meals (MTMs) Other
1 trials
Nutritional Counseling Behavioral
1 trials
Cerebrospinal fluid collection Procedure
1 trials
Evolocumab Drug
1 trials
Erlotinib Drug
1 trials

US sites by state

Facility locations filed on Lung Cancer Metastatic trials. A trial with sites in several states counts in each.

California 3 trials
Texas 2 trials
Pennsylvania 2 trials
Ohio 2 trials
New York 2 trials
New Jersey 2 trials
Vermont 1 trials
Tennessee 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Lung Cancer Metastatic page

9 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lung Cancer Metastatic condition card totals 9 registered trials; most-linked intervention Nutrition Toolkit; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.